Treatment with Alpelisib in ER+ breast cancer cells or patients with primary tumors resulted in activation of ERα via lysine methyltransferase 2D (KMT2D)-dependent FOXA1-PBX1 complex [57]. The gene discussed is KMT2D; the disease is breast carcinoma.